Q-omics provides the consensus-scored DEFB130C profile across patient tissues and cancer cell-line models. DEFB130C expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, DEFB130C is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, DEFB130C RNA expression shows 9,913 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, BRCA, and LSCC as cancer lineages where DEFB130C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DEFB130C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DEFB130C survival associations across molecular data types. DEFB130C RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DEFB130C RNA expression–survival associations across cancer types. High DEFB130C expression shows unfavorable associations in MESO, LUSC, ACC, PCPG, SKCM and UCEC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for DEFB130C RNA expression.
This table summarizes DEFB130C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for DEFB130C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DEFB130C shows lower tumor expression in THCA and higher tumor expression in BRCA and LIHC. The BRCA box plot shows higher DEFB130C RNA expression in tumor versus normal tissue (log2 FC = +0.179, t-test p = .024).
This table shows molecular features associated with DEFB130C in patient tissues and cancer cell lines. In patient samples, DEFB130C shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
